Aim: :Stroke is one of the most destructive neurological
events. Diabetes mellitus confirmed asindependent risk factor. The studyaimed to correlate the effect of
duration and combination of oral hypoglycemic agents (metformin and
glibenclamide) to the incidence of ischemic stroke in type 2 diabeticpatients.
Methods: A cross-sectional study was carried out on
type 2diabetic patientswith or without history of ischemic
stroke. Patients were divided into: Group I(metformin)and Group II (metformin
and glibenclamide). Laboratory analysis involved metabolic and oxidative
glycemic control (HbA1c<7) was predominant in Group I, poor and very poor glycemic
control (HbA1c>7) were predominant in Group II. Group I revealed significant
decrease in the MDA leveland TG/HDL ratio (P<0.05). While Group
II showed significant increase in HbA1c, TG/HDL ratio, PN, and other metabolic
parameters (TC, TG and HDL)(P˂0.05)
withdecrease in MDA after 5 years duration (P˂0.01).Treatment (<5 years), FBS, HbA1c and TC showed significant correlation with ischemic
stroke (p<0.01). Whiletreatment(>5 years), FBS, HbA1c as well as MDA
showed a significant correlation with ischemic stroke (p<0.05).
Conclusion: Metformin monotherapy significantly
diminishes oxidative stress and restores antioxidant capacity,suggesting better
efficacy compared with co-administration with glibenclamide.
Keywords: Metformin; Metformin and Glibenclamide; Metabolic parameters;Oxidative status; Type 2 DM;Ischemic stroke.